Johnny Mahlangu to Quality of Life
This is a "connection" page, showing publications Johnny Mahlangu has written about Quality of Life.
Connection Strength
3,288
-
Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A. J Thromb Haemost. 2024 Jul; 22(7):1880-1893.
Score: 0,814
-
Health-related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, non-interventional study (NIS). Haemophilia. 2019 May; 25(3):382-391.
Score: 0,577
-
Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study. Haemophilia. 2021 May; 27(3):398-407.
Score: 0,163
-
Health-related quality of life and caregiver burden of emicizumab in children with haemophilia A and factor VIII inhibitors-Results from the HAVEN 2 study. Haemophilia. 2020 Nov; 26(6):1009-1018.
Score: 0,160
-
Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study. Pediatr Blood Cancer. 2020 10; 67(10):e28474.
Score: 0,158
-
Redefining prophylaxis in the modern era. Haemophilia. 2021 Feb; 27 Suppl 3:21-27.
Score: 0,156
-
BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601.
Score: 0,154
-
rFVIIIFC for hemophilia A prophylaxis. Expert Rev Hematol. 2018 12; 11(12):937-943.
Score: 0,140
-
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors. BioDrugs. 2018 Dec; 32(6):561-570.
Score: 0,140
-
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia. 2019 Jan; 25(1):33-44.
Score: 0,140
-
Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 08 30; 379(9):811-822.
Score: 0,138
-
Evaluation of the self-administered bleeding assessment tool (Self-BAT) in haemophilia carriers and correlations with quality of life. Haemophilia. 2017 11; 23(6):e536-e538.
Score: 0,129
-
Uptake of Genetic Counseling, Knowledge of Bleeding risks and Psychosocial Impact in a South African Cohort of Female Relatives of People with Hemophilia. J Genet Couns. 2015 Dec; 24(6):978-86.
Score: 0,109
-
Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1. J Thromb Haemost. 2023 12; 21(12):3450-3462.
Score: 0,049
-
Reclassifying hemophilia to include the definition of outcomes and phenotype as new targets. J Thromb Haemost. 2023 07; 21(7):1737-1740.
Score: 0,047
-
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia. 2021 Sep; 27(5):854-865.
Score: 0,042
-
Core data set on safety, efficacy, and durability of hemophilia gene therapy for a global registry: Communication from the SSC of the ISTH. J Thromb Haemost. 2020 11; 18(11):3074-3077.
Score: 0,040
-
The evolving landscape of gene therapy for congenital haemophilia: An unprecedented, problematic but promising opportunity for worldwide clinical studies. Blood Rev. 2021 03; 46:100737.
Score: 0,039
-
A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019 12 12; 134(24):2127-2138.
Score: 0,038
-
Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies. Haemophilia. 2016 Nov; 22(6):866-872.
Score: 0,030
-
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood. 2014 Dec 18; 124(26):3880-6.
Score: 0,026